Approval Based on Phase 3 Data Showing Veklury Significantly Reduced Risk of Hospitalization By 87% Compared with Placebo NIH Guidelines Recommend Veklury for the Treatment of Non-Hospitalized Patients at High Risk FDA Expands Pediatric…Original Article
FDA Approves Veklury (remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
